30 Mar 2026

CRC Research Update — March 30, 2026

Creator: The CRC Digest
Published: 2026-03-30T11:45:13Z

Today's colorectal cancer research highlights

Was this forwarded to you? Read on the web or subscribe free

IMPORTANT: The CRC Digest curates and summarizes publicly available research for informational and educational purposes only. Nothing in this newsletter constitutes medical advice, diagnosis, or treatment recommendation. The information provided should not be used as a substitute for professional medical advice. Always seek the guidance of your physician or other qualified health provider with any questions regarding a medical condition or treatment. Content is generated with AI assistance and reviewed by the editorial team. We are not medical professionals. Individual results, treatments, and outcomes vary.

Signal Key

TRIAL DATA clinical trial results, efficacy data, survival endpoints TREATMENT new treatment options, regimen changes, combination therapies REGULATORY FDA/EMA approvals, guideline updates, NCCN/ESMO changes RESEARCH cancer biology, biomarker discoveries, resistance pathways SCREENING screening, colonoscopy guidelines, liquid biopsy, molecular profiling LIVING WITH CRC survivorship, quality of life, side effects, patient decision-making, caregiver support

CRC Research Update

Female patients experience greater toxicity from first-line mCRC treatment
Analysis of 18,041 patients across 27 trials found females had significantly higher rates of severe side effects from chemotherapy with or without targeted therapies, though survival outcomes were similar between sexes. (European Journal of Cancer)
Phase 2 trial tests gentler first-line options for elderly mCRC patients
The ELDERLY trial randomized patients age 70+ or frail to either dose-reduced FOLFOX or aflibercept plus 5-FU, evaluating tolerability and efficacy in patients not eligible for full-dose combinations. (European Journal of Cancer)
Multi-target stool DNA test shows high adherence in real-world health system
Massachusetts General Hospital data revealed strong patient adherence to mt-sDNA testing and examined completion rates for follow-up colonoscopy after positive results, providing insights into screening implementation. (Current Medical Research and Opinion)
Urinary extracellular vesicles show promise for minimal residual disease detection
Study of 160 CRC patients compared urinary EVs to plasma ctDNA for liquid biopsy, finding urinary EVs may offer a non-invasive option for monitoring disease after surgery. (Cancer Science)

⚥ Sex & Gender in CRC

Research on sex-specific differences in treatment, outcomes, and screening

Females face higher chemotherapy toxicity in metastatic disease
Large database analysis confirms females experience more severe side effects from standard mCRC regimens despite similar survival benefits. (European Journal of Cancer)

🔎 Screening Watch

Screening guidelines, early detection, and prevention advances

Asian screening programs compared across Japan, South Korea, and Taiwan
Comprehensive review examines national CRC screening strategies, effectiveness, and quality assurance frameworks in Asia's established programs. (Journal of Gastroenterology and Hepatology)
Study evaluates risk at second surveillance colonoscopy
New Hampshire registry data assessed advanced findings at third colonoscopy based on index adenoma characteristics and first surveillance results. (Clinical Gastroenterology and Hepatology)

Today's research highlights the importance of personalized approaches—from recognizing sex differences in treatment tolerance to optimizing screening strategies for diverse populations.

CRC Research Update

Subscribe to The CRC Digest